The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Inheritance and Drug Response
Open accessAbstract
he promise of pharmacogenetics, the study of the role of in heritance in the individual variation in drug response, lies in its potential to identify the right drug and dose for each patient. Even though individual differences in drug response can result from the effects of age, sex, disease, or drug interactions, genetic factors also influence both the efficacy of a drug and the likelihood of an adverse reaction. 1-3 This article briefly reviews concepts that underlie the emerging fields of pharmacogenetics and pharmacogenomics, with an emphasis on the pharmacogenetics of drug metabolism. Although only a few examples will be provided to illustrate concepts and to demonstrate the potential contribution of pharmacogenetics to medical practice, it is now clear that virtually every pathway of drug metabolism will eventually be found to have genetic variation. The accompanying article by Evans and McLeod 4 expands on many of the themes introduced here. Once a drug is administered, it is absorbed and distributed to its site of action, where it interacts with targets (such as receptors and enzymes), undergoes metabolism, and is then excreted. 5,6 Each of these processes could potentially involve clinically significant genetic variation. However, pharmacogenetics originated as a result of the observation that there are clinically important inherited variations in drug metabolism. Therefore, this article — and the examples highlighted — focuses on the pharmacogenetics of drug metabolism. However, similar principles apply to clinically significant inherited variation in the transport and distribution of drugs and their interaction with their therapeutic targets. The underlying message is that inherited variations in drug effect are common and that some tests that incorporate pharmacogenetics into clinical practice are now available, with many more to follow. The concept of pharmacogenetics originated from the clinical observation that there were patients with very high or very low plasma or urinary drug concentrations, followed by the realization that the biochemical traits leading to this variation were inherited. Only later were the drug-metabolizing enzymes identified, and this discovery was followed by the identification of the genes that encoded the proteins and the DNA-sequence variation within the genes that was associated with the inherited trait. Most of the pharmacogenetic traits that were first identified were monogenic — that is, they involved only a single gene — and most were due to genetic polymorphisms; in other words, the allele or alleles responsible for the variation were relatively common. Although drug effect is a complex phenotype that depends on many factors, early and often dramatic examples involving succinylcholine and isoniazid facilitated acceptance of the fact that inheritance can have an important influence on the effect of a drug. Today there is a systematic search to identify functionally significant variations in DNA sequences in genes that influence the effects of various drugs. 4 t
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N. J., Jansen, P. L. M., Elferink, R. P. J. O., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331802 · Cited by 1,447
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Weinshilboum, R. M., & Sladek, S. L. (1980) · PubMed · Cited by 1,195
Self-citationPOLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A., & Goldstein, J. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40694-6 · Cited by 956
Genetic Control of Isoniazid Metabolism in Man
Evans, D. A. P., Manley, K. A., & McKusick, V. A. (1960) · BMJ · doi:10.1136/bmj.2.5197.485 · Cited by 784
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
Lennard, L., Lilleyman, J. S., Van Loon, J., & Weinshilboum, R. M. (1990) · The Lancet · doi:10.1016/0140-6736(90)91745-v · Cited by 651
Self-citationThe clinical pharmacology of 6-mercaptopurine
Lennard, L. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf02220605 · Cited by 647
Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjöqvist, F., & Ingelman-Sundberg, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11825 · Cited by 644
Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
Eichelbaum, M., Spannbrucker, N., Steincke, B., & Dengler, H. J. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562059 · Cited by 632
Lennard, L., Van Loon, J. A., & Weinshilboum, R. M. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.119 · Cited by 593
Self-citationWeinshilboum, R. M., Otterness, D. M., & Szumlanski, C. L. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.19 · Cited by 549
Self-citationDiasio, R. B., Beavers, T. L., & Carpenter, J. T. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113308 · Cited by 503
Kimura, S., Umeno, M., Skoda, R. C., Meyer, U., & Gonzalez, F. J. (1989) · Europe PMC (PubMed Central) · Cited by 462
Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R., & Branch, R. A. (1985) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1985.194 · Cited by 452
BLUM, M., GRANT, D. M., McBRIDE, W., HEIM, M., & MEYER, U. A. (1990) · DNA and Cell Biology · doi:10.1089/dna.1990.9.193 · Cited by 435
Bertilsson, L., Lou, Y.-Q., Du, Y.-L., Liu, Y., Kuang, T.-Y., Liao, X.-M., Wang, K.-Y., Reviriego, J., Iselius, L., & Sjöqvist, F. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.38 · Cited by 399
Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F., & Ingelman-Sundberg, M. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20152-5 · Cited by 392
Collie-Duguid, E. S. R., Pritchard, Powrie, Sludden, J., Collier, Li, T., & McLeod, H. L. (1999) · Pharmacogenetics · doi:10.1097/00008571-199902000-00006 · Cited by 368
IYER, L., HALL, D., DAS, S., MORTELL, M., RAMIREZ, J., KIM, S., DIRIENZO, A., & RATAIN, M. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70078-0 · Cited by 356
Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., Hanai, H., Kubota, T., Ishizaki, T., & Kaneko, E. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00006 · Cited by 335
SZUMLANSKI, C., OTTERNESS, D., HER, C., LEE, D., BRANDRIFF, B., KELSELL, D., SPURR, N., LENNARD, L., WIEBEN, E., & WEINSHILBOUM, R. (1996) · DNA and Cell Biology · doi:10.1089/dna.1996.15.17 · Cited by 305
Self-citationGenetic analysis of the human cytochrome P450 CYP2C9 locus
Stubbins, M. J., Harries, L. W., Smith, G., Tarbit, M. H., & Wolf, C. R. (1996) · Pharmacogenetics · doi:10.1097/00008571-199610000-00007 · Cited by 300
10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*
Dalén, P., Dahl, M.-L., Ruiz, M. L. B., Nordin, J., & Bertilsson, L. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90040-6 · Cited by 285
Interindividual variability in sensitivity to warfarin-Nature or nurture?
Loebstein, R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117444 · Cited by 260
Tai, H.-L., Krynetski, E. Y., Schuetz, E. G., Yanishevski, Y., & Evans, W. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6444 · Cited by 259
Familial Pyrimidinemia and Pyrimidinuria Associated with Severe Fluorouracil Toxicity
Tuchman, M., Stoeckeler, J. S., Kiang, D. T., OʼDea, R. F., Ramnaraine, M. L. R., & Mirkin, B. L. (1985) · New England Journal of Medicine · doi:10.1056/nejm198507253130407 · Cited by 252
Inheritance of low erythrocyte catechol-o-methyltransferase activity in man.
Weinshilboum, R. M., & Raymond, F. A. (1977) · Europe PMC (PubMed Central) · Cited by 247
Self-citationPharmacogenetics. Heredity and the Response to Drugs.
(1963) · Annals of Internal Medicine · doi:10.7326/0003-4819-58-4-757 · Cited by 242
Raida, M., Schwabe, W., Häusler, P., Kuilenburg, A. B. P., Gennip, A. H., Behnke, D., & Höffken, K. (2001) · PubMed · Cited by 231
Lin, H. J., Han, C. Y., Lin, B. K., & Hardy, S. W. (1993) · Europe PMC (PubMed Central) · Cited by 217
Lampe, J. W., Bigler, J., Horner, N. K., & Potter, J. D. (1999) · Pharmacogenetics · doi:10.1097/00008571-199906000-00009 · Cited by 205
The pharmacogenetics of codeine hypoalgesia
Sindrup, S. H., & Br??sen, K. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512000-00001 · Cited by 201
The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement
van der Weide, J., Steijns, L. S. W., van Weelden, M. J. M., & de Haan, K. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00002 · Cited by 199
McGuire, M. C., Nogueira, C. P., Bartels, C. F., Lightstone, H., Hajra, A., Van der Spek, A. F., Lockridge, O., & La Du, B. N. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.3.953 · Cited by 185
genotype–related efficacy of omeprazole for the treatment of infection caused by
TANIGAWARA, Y., AOYAMA, N., KITA, T., SHIRAKAWA, K., KOMADA, F., KASUGA, M., & OKUMURA, K. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70017-2 · Cited by 182
Polymorphic acetylation of procainamide in man
Reidenberg, M. M., Drayer, D. E., Levy, M., & Warner, H. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975176722 · Cited by 180
Gonzalez, F. J., Vilbois, F., Hardwick, J. P., McBride, O. W., Nebert, D. W., Gelboin, H. V., & Meyer, U. (1988) · Genomics · doi:10.1016/0888-7543(88)90100-0 · Cited by 176
Metabolism of Thiopyrimidines and Thiopurines
Remy, C. N. (1963) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81262-5 · Cited by 172
THE RELATION BETWEEN DOSE OF SUCCINYLCHOLINE AND DURATION OF APNEA IN MAN
KALOW, W., & Gunn, D. R. (1957) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11853-3 · Cited by 161
SOME STATISTICAL DATA ON ATYPICAL CHOLINESTERASE OF HUMAN SERUM
KALOW, W., & GUNN, D. R. (1959) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1959.tb01467.x · Cited by 160
Kroemer, H. K., & Eichelbaum, M. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00223-s · Cited by 160
Hall, D., Ybazeta, G., Destro‐Bisol, G., Petzl‐Erler, M. L., & Rienzo, A. D. (1999) · Pharmacogenetics and Genomics · doi:10.1097/00008571-199910000-00006 · Cited by 151
The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study*
Balian, J. D., Sukhova, N., Harris, J. W., Hewett, J., Pickle, L. W., Goldstein, J. A., Woosley, R. L., & Flockhart, D. A. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90229-5 · Cited by 151
Human kidney thiopurine methyltransferase purification and biochemical properties
Woodson, L. C., & Weinshilboum, R. M. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90582-8 · Cited by 133
Self-citationCatechol-O-methyltransferase activity: A determinant of levodopa response
Reilly, D. K., Rivera‐Calimlim, L., & Dyke, D. V. (1980) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1980.161 · Cited by 124
Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects*
Tybring, G., Böttiger, Y., Widén, J., & Bertilsson, L. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90060-6 · Cited by 101
Nomenclature for human DPYD alleles
McLeod, H. L., Collie-Duguid, E. S. R., Vreken, P., Johnson, M. R., Wei, X., Sapone, A., Diasio, R. B., Fernández‐Salguero, P. M., van Kuilenberg, A. B. P., Gennip, A. H., et al. (1998) · Pharmacogenetics · doi:10.1097/00008571-199812000-00001 · Cited by 94
Genetic Factors in Drug Therapy: Clinical and Molecular Pharmacogenetics
Evans, P., & Dávid, A. (1994) · Cited by 67
Cited by
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Drug Metabolism and Variability among Patients in Drug Response
Wilkinson, G. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra032424 · Cited by 1,185
Pui, C.-H., Relling, M. V., & Downing, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra023001 · Cited by 1,185
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Metadata
- Authors
- Weinshilboum, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-02-06
- Volume
- 348
- Issue
- 6
- Pages
- 529-537
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2314647810
- Cited by
- 1,031
- References
- 54
- FWCI
- 83.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.